Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history.
Fig 1.
Schematic of the prostate cancer natural history model reflecting disease onset, progression and survival in the absence of screening. Individuals are assumed to be healthy at age 35 years; they may progress to preclinical cancer states with fixed Gleason score, but with progression by T-stage and to metastatic cancer; preclinical cancers may be clinically diagnosed from nine different states, with survival from prostate cancer death modelled from the time of clinical diagnosis; death due to other causes is represented as a competing event. Modelled current PSA testing rates per person-year for ages 40-80 years and the calendar period 1995-2014 for men without an existing prostate cancer diagnosis. The white contour lines indicates the rates 0.1, 0.2 and 0.3. The modelled values are based on data from the Stockholm PSA and Biopsy Register [15] . and 2). Importantly, we modelled for transitions between T-stages and fitted the 81 relative distributions for the Gleason scores and cancer T and M stages by age groups; 82 see Fig 3. We included different T-stages to support more detailed modelling of 83 treatment and survival. The use of relative proportions allows for the absolute incidence 84 rates to be used for validation. The calibration used a reconstruction of a contemporary 85 Swedish population with data on PSA test uptake, health state proportions at diagnosis, 86 and survival from a screened population. A total of 4392 diagnoses in the ages 50-74 87 from a three-years interval (2011-2013) were used as calibration targets. Calibration of screening effects on incidence. In addition to the calibration of 91 the screened Swedish population, we also simulated for the screened and unscreened 92 arms from the ERSPC to replicate results from the 13 years of follow-up [7] ; for details 93 on the reconstruction of the ERSPC trial, see Materials and Methods. The ERSPC rate 94 ratio of prostate cancer incidence (1.57, 95% confidence interval (CI) 1.51-1.62) was 95 used in the calibration, while the ERSPC mortality RR of prostate cancer was used for 96 validation. To calibrate to the ERSPC incidence rate ratio and to model indirectly for 97 tumour size, we introduced a parameter for the proportion of the time from onset that a 98 T1-T2 cancer would not be biopsy detectable [16] ; we estimated that the T1-T2 99 cancers would on average be undetectable at biopsy for 47% of the time before they 100 progressed to T3-T4 cancers. Population prostate cancer incidence. In Fig 5, we compared the 119 age-standardised prostate cancer incidence rates from the simulation with that of 120 Sweden during 1985-2016 which included the introduction of PSA testing. There is 121 evidence for a good fit although the rapid increase in incidence following the 122 introduction of PSA testing was not fully captured. This over-smoothing is possibly due 123 to the PSA uptake sub-model having few degrees of freedom. Importantly, this is a 124 validation and we did not calibrate for prostate cancer incidence rates. Screening effect on mortality. In contrast to the incidence increase from ERSPC, 128 which was used for calibration, the mortality decrease was used for validation. Using 
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Model predictions 135
When planning for prostate cancer testing policies, the following measures were 136 considered to represent the burden of disease: prostate cancer incidence rate; prostate 137 cancer overdiagnosis rate, where overdiagnosis is defined as the lifetime risk of having a 138 prostate cancer diagnosis that would never have been clinically detected prior to death 139 due to another cause; prostate cancer mortality rate; and life expectancy. We predicted 140 these measures for a policy that replaces the current testing pattern (see Fig 2) with 141 regular prostate cancer testing during ages 55-69 years: regular testing was introduced 142 from 2015 at age 55 years for those born in 1960 and in later birth cohorts. Using this 143 policy introduction, regular testing had completely replaced current testing across ages 144 55-69 years after 15 years. Our modelling of organised screening only specifically 145 addresses the effect of screening intensity for the targeted age groups.
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In Fig 6, The purpose of early detection for prostate cancer is to lower prostate cancer 162 mortality and increase the life expectancy. To assess these effects, we predicted 163 mortality rates and life-years gained for the different PSA testing policies (Fig 7) . observed in the ERSPC study as the current PSA uptake pattern is less intensive than 181 ERSPC and the lower biopsy compliance observed in Sweden (see Table 2 in the 182 S1 Appendix).
183
The modest mortality reductions are potentially explained by relatively high levels of 184 testing under the current PSA testing, and the use of the currently observed biopsy 185 compliance for all predicted scenarios. These reductions are also comparable to the 186 non-significant mortality reduction found in the Prostate, Lung, Colorectal and Ovarian 187 (PLCO) cancer screening trial [8] , where there were high levels of PSA testing in the 188 control arm [19] . Investigators are divided in how to resolve these challenges. One school uses very 204 simple models with expert judgement for the effectiveness of interventions. The validity 205 of the predictions depend on the accuracy of the experts. A second school uses Markov 206 models fitted to evidence from randomised controlled trials (RCTs) to assess the 207 effectiveness of specific interventions within the follow-up from the RCTs. The validity 208 is limited by the available RCT evidence, with strong limitations for predicting outside 209 of the observed data. A third school uses more detailed natural history models and 210 simulate for individuals. The validity of the predictions primarily reflects the validity of 211 the natural history model. We are firmly in the last of these three schools. We have 212 previously modelled cancer screening using both simple and more complex Markov 213 models, and found issues with validity for the simple models and issues with model 214 complexity for scaling more detailed Markov models to combinations of natural history 215 and test states by time in state [20] .
216
One potential criticism of many microsimulation models for cancer screening is that 217 their complexity is coupled with a lack of model detail and that the source is usually 218 closed. The US-funded CISNET collaboration has provided detailed model 219 documentation [21] and some models (e.g. FHCRC) are available on request. We https://github.com/mclements/prostata). We encourage other microsimulation 223 modellers to make their code openly available, which will lower the entry requirements 224 for other investigators. If the cost of entry remains high, then a closed source consulting 225 model will continue to be predominant.
226
There are several potential limitations. First, the revised natural history model was 227 less accurate for modelling event rates at older ages (e.g. over 80 years of age; 228 see S1 Appendix). This is consistent with observations that Nordic prostate cancer 229 mortality rates are typically higher than rates in US populations. We suggest caution 230 when interpreting incidence for Nordic populations for several reasons: the higher 231 Nordic rates may lead to greater absolute declines in rates, leading to more effective 232 screening; and the point estimate for the mortality reduction due to screening was 233 higher in the Göteborg site, although there was no statistically significant heterogeneity 234 between the ERSPC sites [7, p = 0.4]. More accurate modelling at older ages would 235 require a more detailed natural history model. Second, it is difficult to assess whether 236 the natural history model is causal and accurate: the disease process is only partially 237 observed and the biology represented using a simple mathematical representation.
238
Third, the prediction of age-standardised mortality rates were slightly lower than that 239 observed in the Swedish population. This underestimation could be due to e.g. changes 240 in Gleason grading, where the Gleason and T-stage distribution at diagnosis was based 241 on data from patients diagnosed 2011-2013 whereas the survival by stage was based on 242 patients diagnosed 1998-2014. 243 Finally, as individuals were followed for up to 15 years, the survival calibration was 244 influenced by earlier Gleason grading practices, possibly leading to an overestimation of 245 the risks for Gleason ≤ 6 cancers. Nonetheless, we expect that our predictions will have 246 strong internal validity, as the simulations allow for carefully controlled experimental 247 conditions. 
Materials and Methods
286
In this section, we will describe the various data sources used to develop the model, 287 explain the model formulation, outline the methods for the calibration and validation of 288 the model, and finish with a description of the model implementation.
289
Data sources 290 We have integrated multiple sources of data in order to extract relevant Swedish unique Swedish personal identification number [23] , we linked the study cohort to a 295 number of population registers, including the National Cancer Register (NCR) and the 296 National Prostate Cancer Register (NPCR transitions between natural history disease states, as shown in Fig 1. The PSA growth 318 is expressed functionally in Equation (1) and the transitions between states is defined in 319 equations (5) - (11) . Cancer onset is assumed to be independent of PSA, and that PSA 320 rises faster after cancer onset. The distribution of Gleason score is assumed to be 321 multinomial with the proportions modelled as a function of age at cancer onset, with no 322 de-differentiation (or change in Gleason score) after onset.
323
PSA growth. The change in PSA values after cancer onset is assumed to differ by 324 Gleason score, with a specific change for Gleason score 6 and below (G6-), Gleason 7 325 (G7) and Gleason 8 and above (G8+).
where y i (t) is measured PSA at age t for subject i, I(A) is a 1 if A is true and 0 327 otherwise, t oi is the age of cancer onset and where The random slopes N(µ,σ 2 )I(β>0) are truncated distributions to ensure that PSA 334 growth is monotonically increasing.
335
The values for µ 1 , σ 1 , µ 4 and σ 4 were from [11] , while the estimates for µ 2 , σ 2 , µ 3 336 and σ 3 were weighted sums to separate the estimates of Gleason ≤ 7 from [11] into 337 Gleason ≤ 6 and Gleason 7.
338
Gleason score distribution. The Gleason score assigned to an individual at cancer 339 onset is dependent on the age at cancer onset according to the probabilities modelled 340 via the multinomial logistic regression in Equations (2) -(4) as illustrated in Fig 9   341 (right panel). 
where t ≥ 35. the same for all Gleason categories and is described in Equation (6) . γ t is the hazard of 358 transitioning to T3-T4 and the time-dependence comes from the log-PSA levels.
The rate from T3-T4 to metastatic disease is proportional to PSA and γ m which is 360 the metastasis hazard (see Equation (7)). Note that the FHCRC model used γ t to 361 represent the parameter for the transition rate from onset to metastatic [11] .
The clinical diagnosis rate for localised cancer onset for Gleason score 7 and lower 363 (Equation (8)) and Gleason score 8 and higher (Equation (9)) are proportional to PSA 364 and γ G * lc , which is the clinical diagnosis hazard for localised cancer for the two Gleason 365 score categories. As per the older US model, we combined the Gleason ≤ 6 and 7 scores 366 for these transitions due to a lack of informative data.
The rate to clinical diagnosis after metastatic onset for Gleason score 7 and below 368 (Equation (10)) and Gleason score eight and above (Equation (11)), is proportional to 369 PSA and γ G * mc is the post-metastasis clinical diagnosis hazard for the two Gleason score 370 categories.
PSA testing sub-model. Diffusion of a new health technology into a population is a 372 dynamic process. This process may reach a stationary state after a longer period of time. 373 For PSA testing, test uptake was distributed across a range of ages over a comparatively 374 short period, such that the PSA test patterns varied substantially by birth cohorts.
375
PSA test uptake is required for calibrating the model to screened populations.
376
The natural history model is calibrated to data that are observed both before and 377 since the introduction of PSA testing. In particular, we have survival data for men 378 diagnosed for prostate cancer from 1998, which is after the introduction of PSA testing. 379 This requires that we accurately model for PSA uptake and re-testing and for treatment 380 to represent the men at risk for prostate cancer incidence, survival and mortality.
381
The PSA sub-model represents uptake of the PSA test together with the pattern of PSA re-testing. Uptake was modelled as: (i) a function of age for cohorts born from 1960; (ii) a function of calendar period multiplied by a factor for birth cohort for birth cohorts born before 1932; and (iii) a mixture of (i) and (ii) for the birth cohorts between 1932 and 1960. Mathematically, age-specific uptake (i) is modelled by the cumulative density function for a log-logistic cure model, such that
where t is age at uptake, π 1 is the proportion of men ever having a PSA test, c is the calendar year of birth (or birth cohort), and where a 1 and b 1 are the shape and scale for a log-logistic distribution for those men who ever have a PSA test. The calendar-specific uptake for the older cohorts (ii) is modelled by
where π 2 is the proportion of men who ever have a PSA test, and where a 1 and b 1 are 382 the shape and scale for a log-logistic distribution for those men who ever have a PSA 383 test. Finally, for the intermediate birth cohorts, t 1 is sampled from F 1 , t 2 is sampled 384 from F 2 , and t 1 is selected over t 2 with probability (1960 − c)/ (1960 − 1932) .
385
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PSA re-testing is modelled using a Weibull cure model, such that
, t > t 0 (14) where t 0 is the age at the previous PSA test, y 0 is the value of the previous PSA test, 386 π 3 is the proportion of men who will ever have a re-test, and where a 3 Biopsy sensitivity and compliance. For men who had a PSA value above 3 ng/mL, 394 the proportion complying with a subsequent biopsy varied by PSA values and age, and 395 was estimated from the SPBR (see Table 2 in the S1 Appendix). We also modelled for 396 whether a prostate cancer was biopsy-detectable, assuming that a cancer was not 397 initially detectable for a proportion φ lag (16) -(17) of the time from cancer onset to the 398 development of a T3-T4 cancer. Our approach varied from Wever et al. 2010 [16] , who 399 modelled for the sensitivity of a PSA test to detect a cancer by stage, irrespective of the 400 time from cancer onset. The probability of a biopsy (Bx) rendering a diagnosis (Dx) 401 depends on the biopsy sensitivity, the biopsy compliance and the probability of cancer: 402
where P(t ≥ t 0 ) is the probability of having had a cancer onset, P (Bx comp (t, PSA|PSA + )) is probability of performing a biopsy after a positive PSA test depending on age and PSA value and P (Bx sens ) is the biopsy sensitivity as expressed below:
where ∆ = t T 3−T 4 − t 0 is the time with a T1-T2 cancer.
403 Treatment sub-model. Probabilities for treatment assignment to either active 404 surveillance, radical prostatectomy, radiotherapy or androgen deprivation therapy were 405 assessed from the SBPR. These values were stratified by five year age groups and 406 Gleason score (see Fig 3 in observed Kaplan-Meier estimates for men diagnosed with prostate cancer in Sweden. 416 We did not calibrate to observed survival from the pre-PSA era, as such estimates were 417 not available.
418
One significant modelling challenge is selecting and fitting a mathematical 419 representation for the effect of cancer screening. For cancers with a short period 420 between a screen-detected diagnosis and a counter-factual clinical diagnosis, a common 421 model is to represent differential survival based on changes in stage at diagnosis and 
where ClinicalDx and ScreenDx represents either a clinical diagnosis or a screen-detected diagnosis, respectively, and Treatment(a), Stage(a) PSA(a) are the treatment modality, stage and PSA value at age a, respectively. The treatment sub-model assumes that the hazard ratio from SPCG-4 [27, 0.56] applies comparing both radical prostatectomy and radiation therapy with either watchful waiting or active surveillance. This point estimate is consistent with the point estimate from the PIVOT trial [28] , albeit without the latter being significantly different from one. We then model survival as The model was validated against the population of Sweden and the population of 458 Stockholm [30] (the bottom rows in Table 1 ). For the validation we simulated the 459 observed PSA testing pattern and validated the model against the population data for 460 incidence, all-cause mortality and prostate cancer mortality (results provided in the 461 S1 Appendix).
462
Emulating the ERSPC trial. We performed a simulation experiment to emulate the 463 ERSPC trial, where we predicted both the "control" arm and the "screening" arm with 464 100 million simulated men. Both arms where constructed as flat populations with 465 inclusion between ages 55-69 years after which they where followed for 13 years. For 466 study eligibility, we assumed that the men had not had a prostate cancer diagnosis prior 467 to age 55 years. For the control arm, we assumed no screening. For the screening arm, 468 we assumed four-yearly screening between ages 55 and 69 years. The PSA threshold was 469 assumed to be 3.0 ng/mL, although in fact this varied by study site. We also used the 470 reported biopsy compliance of 85.6%. Treatment and other-cause deaths were assumed 471 to be similar to those observed in Stockholm.
472
Calibration methods 473 We used four sets of targets for our calibration procedure: For target 1, we used a multinomial likelihood with unknown parameters θ = (β 7 , β 8 , γ t , γ m , φ lag ) . The multinomial log-likelihood was defined as
where i is an index over age, j is an index over cancer staging, n i is the observed total 483 count in a particular age group, y ij is the observed count for a combination of age and 484 cancer staging, m i (θ) is the simulated total count, and p ij (θ) is the simulated 485 proportion of individuals in a particular disease state (see Equations (2) -(4) for the 486 multinomial data generating mechanism). The cancer staging for the observed 487 frequencies and simulated proportions were by age and (i) loco-regional cancers by 488 combinations of Gleason score and T-stage, and (ii) metastatic prostate cancers. The 489 intercept terms α 7 and α 8 for the distribution of Gleason score at age 35 years were not 490 identifiable and we assumed that α 7 = log(0.2) and α 8 =log(0.002). Half-cell corrections 491 were performed to handle empty cells in the simulated proportions.
492
For target 2, we used a non-linear equality constraint on the expected time from onset to metastatic cancer to ensure identifiability of progression across T-stages. Formally,
wheret T1-T2 (θ) are the mean simulated transition times from onset to T3-T4, 493 t T3-T4 (θ) are the mean simulated transition times from T3-T4 to metastatic cancer, 494 andt old is the expected mean time from onset to metastatic cancer from a model 495 without separate T stages (25.9 years from the FHCRC model; [12] ).
496
For target 3, we used a non-linear equality constraint on the simulated incidence rate ratio from the ERSPC, where l 3 (θ) = (log(IRR) − log(IRR(θ))) 2 (23) where IRR is the observed PSA screening incidence rate ratio from the ERSPC study 497 and IRR(θ) is the simulated incidence rate ratio for the emulation of the ERSPC study. 498 Formally, the log-likelihood l 123 (θ) for targets 1-3 was l 123 (θ) = l 1 (θ) + w 2 l 2 (θ) + w 3 l3(θ)
where w 2 and w 3 are weights for the non-linear constraints. Note that the equality 499 constraints in targets 2 and 3 were formulated in terms of weighted quadratic penalties. 500 The weights were selected so that the constraints were approximately satisfied 501 (w 2 = 1; w 3 = 10 4 ).
502
To optimise the simulation log-likelihood l 123 (θ), we used the Nelder-Mead 503 optimisation algorithm. For each iteration of the optimisation, we evaluated the 504 log-likelihood by simulating three different scenarios that depended on the parameters θ. 505 From these scenarios, we predicted values that were used in the log-likelihood, including 506 the relative distribution of cancer staging, the mean time from onset to metastatic 507 cancer, and the PSA screening incidence rate ratio for the reconstructed ERSPC trial. 508
The Nelder-Mead algorithm is commonly used to optimise functions for which 509 derivatives are difficult to calculate and for objectives that are not smooth. The 510 standard errors were calculated from the inverse of the Hessian matrix for the negative 511 log-likelihood (see Table 2 ). Given the simulation likelihood, the calculation of the 512 Hessian matrix required that the step size for the finite differences used a larger step 513 size (0.01). (2) -(4) β 8 1.9·10 -1 5.9·10 -4 (2) -(4) γ t 9.7·10 -4 6.9·10 -5 (6) γ m 1.5·10 -3 2.0·10 -4 (7) φ lag 5.3·10 
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where S(t|Age, Gleason, PSA, metastatic;θ) is the simulated survival to time t based on 523 the parameters from step 1 and S(t|Age, Gleason, PSA, metastatic) is observed survival 524 to time t from the NPCR.
525
Validation of the ERSPC mortality rate ratio. To validate against the ERSPC 526 screening mortality RR of 0.79 (95% CI 0.61-0.88), we performed a simulation 527 experiment to emulate the ERSPC trial (see Emulating the ERSPC trial). The 528 mortality hazard ratio comparing the screening arm with the control arm was estimated 529 using Poisson regression taking account of the number of prostate cancer deaths and the 530 person-time by one-year age groups. Our validation predictions resulted in a mortality 531 RR of 0.784 (95% Monte Carlo interval (MCI) 0.781-0.786).
532
